Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Of Prostate Clear all
Active, not recruiting Phase 2 Interventional Results available

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

NCT03412396
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

NCT02814669
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer
Interventions
Atezolizumab, Radium-223 Dichloride
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Indoximod, Sipuleucel-T, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 15, 2026, 10:27 AM EDT
Not listed Not applicable Interventional

Physical Therapy for Men Undergoing Prostatectomy

NCT02558946
View directory record Official record
Conditions
Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
Interventions
Pelvic Floor Muscle Physical Therapy, Control Group
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

NCT06171269
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, MRI, Androgen Deprivation Therapy
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

NCT01140373
View directory record Official record
Conditions
Prostate Cancer
Interventions
engineered autologous T cells, cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients

NCT02997709
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
30 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of the AMS CONTINUUM™ Device

NCT00894933
View directory record Official record
Conditions
Prostate Cancer
Interventions
CONTINUUM™
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
40 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Burlington, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

NCT01774071
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr DFO-MSTP2109A
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 15, 2026, 10:27 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

NCT04147806
View directory record Official record
Conditions
Prostate Cancer
Interventions
IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone, Tamsulosin
Radiation · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

NCT06085664
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
REGN5678, Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Not listed Phase 2 Interventional Results available

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04033432
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
Interventions
Recombinant EphB4-HSA Fusion Protein
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Early Phase 1 Interventional

HCQ in Resectable Localized Prostate Cancer

NCT06408298
View directory record Official record
Conditions
Resectable Localized Prostate Cancer
Interventions
Hydroxychloroquine Sulfate 400Mg Tab, Placebo
Drug
Lead sponsor
Lionel.D.Lewis, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Recruiting Phase 1 Interventional

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

NCT05805371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Lymphodepletion Therapy
Biological · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Phase 1 Interventional

Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer

NCT00313534
View directory record Official record
Conditions
Prostate Cancer
Interventions
masoprocol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 15, 2026, 10:27 AM EDT
Completed No phase listed Observational

Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

NCT02518698
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years to 88 Years · Male only
Enrollment
1,163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 15, 2026, 10:27 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer

NCT02648919
View directory record Official record
Conditions
Prostate Cancer
Interventions
Noni extract
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
55 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 1 Interventional

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436
View directory record Official record
Conditions
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions
Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 15, 2026, 10:27 AM EDT
Withdrawn Not applicable Interventional

Single-Port Versus Multi-Port Robotic Radical Prostatectomy

NCT04696263
View directory record Official record
Conditions
Malignant Neoplasm of Prostate
Interventions
Da Vinci ® Xi system - MP Robotic Radical Prostatectomy, Da Vinci ® SP system - SP Robotic Radical Prostatectomy
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 15, 2026, 10:27 AM EDT
Withdrawn No phase listed Observational

Shared Decision Making in Low Risk Prostate Cancer

NCT01673581
View directory record Official record
Conditions
Prostate Cancer
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 15, 2026, 10:27 AM EDT
Withdrawn Not applicable Interventional

Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer

NCT03823001
View directory record Official record
Conditions
Prostate Cancer
Interventions
virtual biopsy (VB) monitoring protocol
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

NCT02463799
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, Sipuleucel-T
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Conservative Treatment of Postprostatectomy Incontinence

NCT00212264
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Behavioral Therapy, Pelvic Floor Electrical Stimulation, Biofeedback, No Treatment
Behavioral · Device · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Male only
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 15, 2026, 10:27 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

NCT00216099
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pemetrexed, Folic Acid, Vitamin B12
Drug · Dietary Supplement
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
Galesburg, Illinois • Elkhart, Indiana • Fort Wayne, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 15, 2026, 10:27 AM EDT